Abstract
Genome editing reagents including the recently introduced CRISPR/Cas9 system have become established and widely used molecular tools to answer fundamental biological questions and to target and treat genetic diseases. The CRISPR system, originally derived from bacteria and archaea, can be delivered into cells using different techniques, comprising (1) transfection of mRNA or plasmid DNA, (2) electroporation of plasmid DNA or the Cas9 protein in a complex with a g(uide)RNA, or (3) use of nonviral or viral vectors. Among the latter, Adeno-associated viruses (AAVs) are particularly attractive owing to many favorable traits: (1) their apathogenicity and episomal persistence, (2) the ease of virus production and purification, (3) the safe handling under lowest biosafety level 1 conditions, and (4) the availability of numerous natural serotypes and synthetic capsid variants with distinct cell specificities. Here, we describe a fast and simple protocol for small-scale packaging of CRISPR/Cas9 components into AAV vectors. To showcase its potential, we employ this method for screening of gRNAs targeting the murine miR-122 locus in Hepa1–6 cells (using AAV serotype 6, AAV6) or the 5′LTR of the human immunodeficiency virus (HIV) in HeLaP4-NLtr cells (using a synthetic AAV9 variant). We furthermore provide a detailed protocol for large-scale production of purified AAV/CRISPR vector stocks that permit higher cleavage efficiencies in vitro and are suitable for direct in vivo applications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cong L, Ran FA, Cox D et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. https://doi.org/10.1126/science.1231143
Mali P, Yang L, Esvelt KM et al (2013) RNA-guided human genome engineering via Cas9. Science 339:823–826. https://doi.org/10.1126/science.1232033
Barrangou R, Doudna JA (2016) Applications of CRISPR technologies in research and beyond. Nat Biotechnol 34:933–941. https://doi.org/10.1038/nbt.3659
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–821. https://doi.org/10.1126/science.1225829
Boettcher M, McManus MT (2015) Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol Cell 58:575–585. https://doi.org/10.1016/j.molcel.2015.04.028
Doudna JA, Charpentier E (2014) Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346:1258096. https://doi.org/10.1126/science.1258096
Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262–1278. https://doi.org/10.1016/j.cell.2014.05.010
Porteus M (2016) Genome editing: a new approach to human therapeutics. Annu Rev Pharmacol Toxicol 56:163–190. https://doi.org/10.1146/annurev-pharmtox-010814-124454
Dominguez AA, Lim WA, Qi LS (2016) Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol 17:5–15. https://doi.org/10.1038/nrm.2015.2
Gilbert LA, Horlbeck MA, Adamson B et al (2014) Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159:647–661. https://doi.org/10.1016/j.cell.2014.09.029
Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173–1183. https://doi.org/10.1016/j.cell.2013.02.022
Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD (2014) A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell 159:635–646. https://doi.org/10.1016/j.cell.2014.09.039
Kearns NA, Pham H, Tabak B, Genga RM, Silverstein NJ, Garber M, Maehr R (2015) Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods 12:401–403. https://doi.org/10.1038/nmeth.3325
Thakore PI, D’Ippolito AM, Song L et al (2015) Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods 12:1143–1149. https://doi.org/10.1038/nmeth.3630
Grimm D, Zolotukhin S (2015) E Pluribus Unum: 50 years of research, millions of viruses, and one goal--tailored acceleration of AAV evolution. Mol Ther 23:1819–1831. https://doi.org/10.1038/mt.2015.173
Schmidt F, Grimm D (2015) CRISPR genome engineering and viral gene delivery: a case of mutual attraction. Biotechnol J 10:258–272. https://doi.org/10.1002/biot.201400529
Epstein BE, Schaffer DV (2017) Combining engineered nucleases with adeno-associated viral vectors for therapeutic gene editing. Adv Exp Med Biol 1016:29–42. https://doi.org/10.1007/978-3-319-63904-8_2
Schmelas C, Grimm D (2018) Split Cas9, Not hairs - advancing the therapeutic index of CRISPR Technology. Biotechnol J 13(9):e1700432. https://doi.org/10.1002/biot.201700432
Senis E, Fatouros C, Grosse S et al (2014) CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol J 9:1402–1412. https://doi.org/10.1002/biot.201400046
Swiech L, Heidenreich M, Banerjee A et al (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33:102–106. https://doi.org/10.1038/nbt.3055
Chew WL, Tabebordbar M, Cheng JK et al (2016) A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods 13:868–874. https://doi.org/10.1038/nmeth.3993
Long C, Amoasii L, Mireault AA et al (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351:400–403. https://doi.org/10.1126/science.aad5725
Nelson CE, Hakim CH, Ousterout DG et al (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351:403–407. https://doi.org/10.1126/science.aad5143
Tabebordbar M, Zhu K, Cheng JKW et al (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351:407–411. https://doi.org/10.1126/science.aad5177
Chow RD, Guzman CD, Wang G et al (2017) AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci 20:1329–1341. https://doi.org/10.1038/nn.4620
Wang G, Chow RD, Ye L et al (2018) Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci Adv 4:eaao5508. https://doi.org/10.1126/sciadv.aao5508
Platt RJ, Chen S, Zhou Y et al (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159:440–455. https://doi.org/10.1016/j.cell.2014.09.014
Ran FA, Cong L, Yan WX et al (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186–191. https://doi.org/10.1038/nature14299
Grimm D, Streetz KL, Jopling CL et al (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537–541. https://doi.org/10.1038/nature04791
McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ (2003) Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10:2112–2118. https://doi.org/10.1038/sj.gt.3302134
McCarty DM, Monahan PE, Samulski RJ (2001) Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8:1248–1254. https://doi.org/10.1038/sj.gt.3301514
Zolotukhin S, Byrne BJ, Mason E et al (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6:973–985. https://doi.org/10.1038/sj.gt.3300938
Kotterman MA, Schaffer DV (2014) Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 15:445–451. https://doi.org/10.1038/nrg3742
Zincarelli C, Soltys S, Rengo G, Rabinowitz JE (2008) Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16:1073–1080. https://doi.org/10.1038/mt.2008.76
Weinmann J, Grimm D (2017) Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53(5):707–713. https://doi.org/10.1007/s11262-017-1502-7
Ellis BL, Hirsch ML, Barker JC, Connelly JP, Steininger RJ 3rd, Porteus MH (2013) A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J 10:74. https://doi.org/10.1186/1743-422X-10-74
Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM (2010) Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther 21:1259–1271. https://doi.org/10.1089/hum.2010.055
Strobel B, Miller FD, Rist W, Lamla T (2015) Comparative analysis of cesium chloride- and iodixanol-based purification of recombinant adeno-associated viral vectors for preclinical applications. Hum Gene Ther Methods 26:147–157. https://doi.org/10.1089/hgtb.2015.051
Guschin DY, Waite AJ, Katibah GE, Miller JC, Holmes MC, Rebar EJ (2010) A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol 649:247–256. https://doi.org/10.1007/978-1-60761-753-2_15
Ran FA, Hsu PD, Lin CY et al (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154:1380–1389. https://doi.org/10.1016/j.cell.2013.08.021
BeckmanCoulter (2014) Using K-factor to compare rotor efficiency. Technical guide CENT-66APP0. www.beckmancoulter.com
Acknowledgments
J.F. and D.G. are grateful for funding from the Cystic Fibrosis Foundation Therapeutics (CFFT, grant number GRIMM15XX0) as well as from the Heidelberg Biosciences International Graduate School HBIGS at Heidelberg University. D.G. acknowledges funding by the Collaborative Research Center SFB1129 (German Research Foundation [DFG], project TP2), the Cluster of Excellence CellNetworks (DFG; EXC81), and the Transregional DFG Collaborative Research Center TRR179 (project TP18, Projektnummer 272983813). M.N. and D.G. are grateful for additional funding from the German Center for Infection Research (DZIF; TTU-HIV 04.803). Moreover, M.N. appreciates funding from the Heidelberg Innovation fund FRONTIER (project “A CRISPR way to eradicate viral pathogens”).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Fakhiri, J., Nickl, M., Grimm, D. (2019). Rapid and Simple Screening of CRISPR Guide RNAs (gRNAs) in Cultured Cells Using Adeno-Associated Viral (AAV) Vectors. In: Luo, Y. (eds) CRISPR Gene Editing. Methods in Molecular Biology, vol 1961. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9170-9_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9170-9_8
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9169-3
Online ISBN: 978-1-4939-9170-9
eBook Packages: Springer Protocols